Trials / Unknown
UnknownNCT00146913
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Sixty % of CML patients treated by Imatinib mesylate achieved a major cytogenetic responses (CCR) at 18 months. So, 40% of the patients must receive additional treatment. In vitro, it has been shown that IM and Interféron-alpha have synergic anti-proliferative effect on chromosome Ph+ cell lines. By using Peg-Interféron and IM combination, we hope to increase the cytogenetic response of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib mesylate 600mg/day | |
| DRUG | Peg-Interféron at 90 microg/week |
Timeline
- Start date
- 2004-03-01
- First posted
- 2005-09-07
- Last updated
- 2007-04-27
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00146913. Inclusion in this directory is not an endorsement.